Share the Video:

Lessons from the first three years of psychedelic public companies

Patrick Trucchio, Florian Brand, George Tziras, Tim Chang

It was not so long ago that the number of publicly-listed psychedelic businesses stood at zero. Over the last three years, numerous psychedelic drug developers and related companies have debuted on both American and Canadian exchanges, rapidly creating a multibillion dollar market. However, the path from drug discovery to approval is long, and the confidence of the market has ebbed since its peak in 2021, and much work (and fundraising) still remains to be done. Join us to hear reflections and predictions from psychedelic industry executives, investors, and analysts about the early days of psychedelic public companies.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

The evolving financial landscape for psychedelic medicine

Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.

Henry Elkus

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Research and Science

Updates from leading statewide regulatory initiatives - Oregon

Oregon’s Psilocybin Services Act and Colorado’s Natural Medicine Health Act are pioneering successful statewide initiatives regulating adult psychedelic substance use, influencing drug policy reforms in eleven other states in 2023.

Angela E Albee, Sam Chapman

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science Social Justice

Intellectual property: shadows and solutions

Traditional cultures use psychedelics, but companies are patenting therapies and compounds based on them. Discussion explores IP system improvements for innovation and public health protection.

Chris Byrnes, Laurel Kilgour, Leslie Booher

PS2023 Business Policy Psychedelic Science Public Benefit Research Social and Cultural

Aligning funding and public benefit in psychedelic businesses

Panel: New psychedelic entrepreneurs discuss unique business structures and financial strategies aligning with values and purpose, rejecting traditional models for innovative, purpose-driven for-profit ventures.

Daniel Tarockoff, Scarlet Masius

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research Research and Science

What Will People Think? Revealing Public Knowledge, Belief, and Perceptions of Psychedelics

Imran Khan presents findings of the Psychedelic Insight Poll, a national survey by the Berkeley Center for the Science of Psychedelics to understand public perceptions of psychedelic substances. The poll

Imran Khan

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Research and Science

Updates from leading statewide regulatory initiatives - Colorado

Oregon’s Psilocybin Services Act and Colorado’s Natural Medicine Health Act are pioneering successful statewide initiatives regulating adult psychedelic substance use. Leaders discuss challenges and lessons learned in implementation.

Rev Veronica Lightning Horse P…, Ean Seeb, Hadas Alterman

PS2023 Health Equity Integration Policy Psychedelic Assisted Therapy Public Benefit Research and Science

Building the next generation of psychedelic care clinics

Integration of psychedelic therapy into healthcare requires clinics to provide safe care. Planning infrastructure carefully, considering environmental factors, is crucial for successful delivery of psychedelic services.

Daniel Kelly, Gregory Kearns, Payton Nyquvest

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Visionary approaches: psychedelic policy in a global context

International drug policy, historically mirroring US prohibitionist approach, is evolving. Leaders propose regulatory solutions in context of broader drug reform for unified post-prohibition world.

Steve Rolles, Kasia Malinowska

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Building momentum for new state policy approaches

Expansion of psychedelic policy in the US includes decriminalization, adult use regulations, and increased research funding. Elected state lawmakers discuss challenges, opportunities, and lessons from proposed psychedelic legislation.

Rep La Shawn Ford (IL), Rep Alex Dominguez (TX), Tamar Todd

Lessons from the first three years of psychedelic public companies

Become a MAPS Member with a monthly donation

Related Videos